Fujian Tianma Science & Technology: A Company in Crisis or a Resilient Survivor?
The latest trading data for Fujian Tianma Science & Technology (603668.SS) reveals a company that has been dragged into a relentless downward spiral. A flat 0 % move in the 24‑hour window ending 04:49 PM Central Europe masks a staggering 39.9 % decline since the end of last month, underscoring a persistent lack of confidence among investors. With a market capitalisation of CNH 505.3 million and a daily turnover of CNH 452.3 million, the firm’s liquidity is stretched thin; its 200‑day simple moving average of CNH 11.06 sits far above its current trading price of CNH 7.1, signalling a potential overvaluation or, more plausibly, a market mis‑pricing of risk.
Judicial Freeze: A Spectre Over Ownership
The company’s own press release confirms that portions of its controlling shareholder’s holdings have been frozen by court order, affecting roughly a quarter of the shares held by the principal shareholder and its affiliated group. The freeze was triggered by a creditor’s request to preserve assets. While the company insists that the ownership structure remains unchanged and day‑to‑day operations are unaffected, the very fact that a major stakeholder is subject to judicial restraint raises red flags. It suggests that the company’s financial base is eroded enough for creditors to take drastic measures, and that the principal shareholder may be struggling to meet its obligations.
New Litigation and Subsidiary Freeze
In addition to the shareholder freeze, Fujian Tianma is embroiled in a new litigation over a modest sum relative to its net assets. More concerning is a court order to freeze a significant stake in a subsidiary for three years, a move that will further constrict capital mobility. These legal entanglements, coupled with an already strained debt profile—overdue loans and notes that constitute a sizeable portion of its net assets—paint a picture of a company in financial distress.
Debt‑Heavy Structure and Temporary Relief
Although the firm has secured extensions on some borrowings, these are only temporary reprieves. The company’s strategy of debt restructuring, asset mobilisation, and tighter capital discipline is reactive rather than proactive. There is no clear long‑term plan to reduce leverage, improve cash flow, or generate sustainable earnings. Investors should therefore treat the company’s current performance as a warning signal rather than a sign of robust resilience.
Market Context and Peer Comparison
Fujian Tianma’s plight must be viewed against the broader backdrop of Chinese market volatility. On October 22, the Shanghai Composite and Shenzhen component indices dipped modestly, while the ChiNext index fell more sharply, reflecting a broader market pullback. In the same period, peer companies such as Hubei Juneyao Great Health, Zhejiang Yankon L, Jinbei Automotive, Zhejiang Aokang Shoes, and Shanghai Laiyifen remained flat, signalling a general lack of momentum across the board.
However, unlike these peers—many of which are pivoting to new product lines or stabilising their supply chains—Fujian Tianma has not demonstrated any strategic shift. While it continues to manufacture aquatic feeds for domestic customers, its website (www.jolma.cn ) offers no evidence of diversification or innovation to counterbalance its financial woes.
Conclusion
The combination of a judicial freeze on a substantial portion of the controlling shareholder’s stake, ongoing litigation, a frozen subsidiary, and an over‑leveraged debt structure raises serious concerns about Fujian Tianma Science & Technology’s future. The company’s current trading performance, a flat 0 % move with a price that is significantly below its 200‑day average, signals that investors are already sceptical of any immediate turnaround. Unless the company can deliver a credible, long‑term restructuring plan that addresses its debt burden and restores operational confidence, Fujian Tianma will continue to languish as a cautionary tale in the Chinese corporate landscape.